Leukotriene A 4 Hydrolase to show increase in growth, 2017

Leukotriene A 4 Hydrolase

Summary 

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Cardiovascular, Respiratory, Dermatology and Hematological Disorders which include indications Pulmonary Arterial Hypertension, Acne Vulgaris, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Emphysema and Lymphedema.

The latest report Leukotriene A 4 Hydrolase - Pipeline Review, H1 2017, outlays comprehensive information on the Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics development with respective active and dormant or discontinued projects.

 @ http://www.wiseguyreports.com/sample-request/1473952-leukotriene-a-4-hydrolase-lta-4-hydrolase-or-leukotriene-a4-hydrolase

Scope of the Report

- The report provides a snapshot of the global therapeutic landscape for Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6)
- The report reviews Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

 Table of Contents 

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Overview
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Companies Involved in Therapeutics Development
Celtaxsys Inc

  .Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1473952-leukotriene-a-4-hydrolase-lta-4-hydrolase-or-leukotriene-a4-hydrolase

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)